Literature DB >> 22420894

Differential proteomic distribution of TTR (pre-albumin) forms in serum and HDL of patients with high cardiovascular risk.

Judit Cubedo1, Teresa Padró, Rodrigo Alonso, Juan Cinca, Pedro Mata, Lina Badimon.   

Abstract

UNLABELLED: Inflammation is a common condition contributing to cardiovascular disease progression which leads to clinical manifestations such as acute myocardial infarction (AMI). By applying a proteomic expression profiling approach we have investigated changes in transthyretin (TTR) in AMI-patients and its distribution patterns in HDL samples of patients with high cardiovascular risk, such as those with familiar hypercholesterolemia (FH). METHODS AND
RESULTS: The characterization by bidimensional electrophoresis (2-DE), followed by mass-spectrometry (MALDI-TOF) of serum samples revealed changes in the intensity of the TTR spot with a pI of 5.6 and a Mw of 42kDa (tTTR) between AMI-patients in association to diabetic dyslipemia. Serum TTR levels, determined by commercial ELISA, were significantly lower (p<0.0001) in AMI-patients (n=39) and FH-patients (n=100) than in healthy controls (n=60). Western blot and 2-DE analysis showed a differential distribution profile of TTR forms between serum, where 3 TTR forms of 42 (tTTR), 28 (dTTR), and 14kDa (mTTR) were detected, and HDL samples, where only mTTR was present.
CONCLUSIONS: Our results demonstrate alterations in TTR proteomic profile in relation to the clustering of risk factors which seems to highlight the implication of TTR in cardiovascular risk. The significant differences in TTR between serum (tTTR) and HDL (mTTR) underscore the importance of TTR-forms in the circulation and deserve further investigation to understand their function.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22420894     DOI: 10.1016/j.atherosclerosis.2012.02.024

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  11 in total

1.  Changes in the proteomic profile of blood serum in coronary atherosclerosis.

Authors:  Ekaterina M Stakhneva; Irina A Meshcheryakova; Evgeny A Demidov; Konstantin V Starostin; Sergey E Peltek; Michael I Voevoda; Yuliya I Ragino
Journal:  J Med Biochem       Date:  2020-01-23       Impact factor: 3.402

2.  ApoL1 levels in high density lipoprotein and cardiovascular event presentation in patients with familial hypercholesterolemia.

Authors:  Judit Cubedo; Teresa Padró; Rodrigo Alonso; Pedro Mata; Lina Badimon
Journal:  J Lipid Res       Date:  2016-04-25       Impact factor: 5.922

Review 3.  Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.

Authors:  Chiz-Tzung Chang; Chao-Yuh Yang; Fuu-Jen Tsai; Shih-Yi Lin; Chao-Jung Chen
Journal:  Biomed Res Int       Date:  2015-05-18       Impact factor: 3.411

4.  Proteomic analysis of plasma-purified VLDL, LDL, and HDL fractions from atherosclerotic patients undergoing carotid endarterectomy: identification of serum amyloid A as a potential marker.

Authors:  Antonio J Lepedda; Gabriele Nieddu; Elisabetta Zinellu; Pierina De Muro; Franco Piredda; Anna Guarino; Rita Spirito; Franco Carta; Francesco Turrini; Marilena Formato
Journal:  Oxid Med Cell Longev       Date:  2013-12-24       Impact factor: 6.543

5.  Modifications in rat plasma proteome after remote ischemic preconditioning (RIPC) stimulus: identification by a SELDI-TOF-MS approach.

Authors:  Pierre Hibert; Delphine Prunier-Mirebeau; Olivia Beseme; Maggy Chwastyniak; Sophie Tamareille; Florence Pinet; Fabrice Prunier
Journal:  PLoS One       Date:  2014-01-13       Impact factor: 3.240

6.  Retinol-binding protein 4 and its potential roles in hypercholesterolemia revealed by proteomics.

Authors:  Watcharapong Jugnam-Ang; Supitcha Pannengpetch; Patcharee Isarankura-Na-Ayudhya; Chadinee Thippakorn; Chartchalerm Isarankura-Na-Ayudhya; Ratana Lawung; Virapong Prachayasittiku
Journal:  EXCLI J       Date:  2015-08-28       Impact factor: 4.068

Review 7.  Pharmacological Intervention to Modulate HDL: What Do We Target?

Authors:  Nicholas J Woudberg; Sarah Pedretti; Sandrine Lecour; Rainer Schulz; Nicolas Vuilleumier; Richard W James; Miguel A Frias
Journal:  Front Pharmacol       Date:  2018-01-22       Impact factor: 5.810

8.  Q-Rich Yeast Prion [PSI+] Accelerates Aggregation of Transthyretin, a Non-Q-Rich Human Protein.

Authors:  Meenakshi Verma; Amandeep Girdhar; Basant Patel; Nirmal K Ganguly; Ritushree Kukreti; Vibha Taneja
Journal:  Front Mol Neurosci       Date:  2018-03-13       Impact factor: 5.639

Review 9.  Prevalence, Treatment, and Control of Hypercholesterolemia in High Cardiovascular Risk Patients: Evidences from a Systematic Literature Review in Spain.

Authors:  Alex de la Sierra; Xavier Pintó; Carlos Guijarro; José López Miranda; Daniel Callejo; Jesús Cuervo; Rudi Subirà; Marta Rubio
Journal:  Adv Ther       Date:  2015-10-26       Impact factor: 3.845

10.  Low serum prealbumin levels on admission can independently predict in-hospital adverse cardiac events in patients with acute coronary syndrome.

Authors:  Wei Wang; Chun-Song Wang; Dong Ren; Tai Li; Heng-Chen Yao; Sheng-Jun Ma
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.